Literature DB >> 19403757

A mutation in helicase motif IV of herpes simplex virus type 1 UL5 that results in reduced growth in vitro and lower virulence in a murine infection model is related to the predicted helicase structure.

Subhajit Biswas1, Ricardo Núñez Miguel2, Soumi Sukla1, Hugh J Field1.   

Abstract

A variant was selected from a clinical isolate of herpes simplex virus type 1 (HSV-1) during a single passage in the presence of a helicase-primase inhibitor (HPI) at eight times the IC(50). The variant was approximately 40-fold resistant to the HPI BAY 57-1293 and it showed significantly reduced growth in tissue culture with a concomitant reduction in virulence in a murine infection model. The variant contained a single mutation (Asn342Lys) in the UL5 predicted functional helicase motif IV. The Asn342Lys mutation was transferred to a laboratory strain, PDK cl-1, and the recombinant acquired the expected resistance and reduced growth characteristics. Comparative modelling and docking studies predicted the Asn342 position to be physically distant from the HPI interaction pocket formed by UL5 and UL52 (primase). We suggest that this mutation results in steric/allosteric modification of the HPI-binding pocket, conferring an indirect resistance to the HPI. Slower growth and moderately reduced virulence suggest that this mutation might also interfere with the helicase-primase activity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19403757     DOI: 10.1099/vir.0.011221-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  7 in total

Review 1.  Progress in the development of new therapies for herpesvirus infections.

Authors:  Nathan B Price; Mark N Prichard
Journal:  Curr Opin Virol       Date:  2011-12       Impact factor: 7.090

2.  Pharmacokinetics-pharmacodynamics of the helicase-primase inhibitor pritelivir following treatment of wild-type or pritelivir-resistant virus infection in a murine herpes simplex virus 1 infection model.

Authors:  Subhajit Biswas; Soumi Sukla; Thomas Goldner; Hugh J Field; Dirk Kropeit; Daniela Paulsen; André Welbers; Helga Ruebsamen-Schaeff; Holger Zimmermann; Alexander Birkmann
Journal:  Antimicrob Agents Chemother       Date:  2014-04-21       Impact factor: 5.191

3.  Antiviral Drugs Against Herpesviruses.

Authors:  Jocelyne Piret; Guy Boivin
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 4.  The DNA helicase-primase complex as a target for herpes viral infection.

Authors:  Sandra K Weller; Robert D Kuchta
Journal:  Expert Opin Ther Targets       Date:  2013-08-12       Impact factor: 6.902

5.  Characterizing the molecular basis of attenuation of Marek's disease virus via in vitro serial passage identifies de novo mutations in the helicase-primase subunit gene UL5 and other candidates associated with reduced virulence.

Authors:  Evin Hildebrandt; John R Dunn; Sudeep Perumbakkam; Masahiro Niikura; Hans H Cheng
Journal:  J Virol       Date:  2014-03-19       Impact factor: 5.103

6.  Non-cytopathic herpes simplex virus type-1 isolated from acyclovir-treated patients with recurrent infections.

Authors:  Subrata Roy; Soumi Sukla; Abhishek De; Subhajit Biswas
Journal:  Sci Rep       Date:  2022-01-25       Impact factor: 4.379

7.  Characteristics of Helicase-Primase Inhibitor Amenamevir-Resistant Herpes Simplex Virus.

Authors:  Yuko Sato; Tadahiro Suenaga; Makoto Kobayashi; Nozomu Miyazaki; Takato Suzuki; Ken Ishioka; Tatsuo Suzutani
Journal:  Antimicrob Agents Chemother       Date:  2021-07-06       Impact factor: 5.191

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.